{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:50Z","timestamp":1792173530042,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neurol.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T21:17:29Z","timestamp":1711660649000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-5294","authenticated-orcid":false,"given":"S.","family":"Demuth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5582","authenticated-orcid":false,"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.01.008_bib0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","article-title":"Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study","volume":"19","author":"Demuth","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2024.01.008_bib0330","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0335","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0340","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0345","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0350","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.01.008_bib0355","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.01.008_bib0360","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0365","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.01.008_bib0370","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0375","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Suppl. 2","key":"10.1016\/j.neurol.2024.01.008_bib0380","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.neurol.2024.01.008_bib0385","doi-asserted-by":"crossref","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2024.01.008_bib0390","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.4679","article-title":"Interleukin-6, a major cytokine in the central nervous system","volume":"8","author":"Erta","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.neurol.2024.01.008_bib0395","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders\u00a0\u2013\u00a0from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0400","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acn3.418","article-title":"CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder","volume":"4","author":"Kowarik","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0405","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0410","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.neurol.2024.01.008_bib0415","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.01.008_bib0420","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0425","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0430","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0440","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0445","doi-asserted-by":"crossref","first-page":"102175","DOI":"10.1016\/j.msard.2020.102175","article-title":"Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules","volume":"43","author":"Trewin","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.01.008_bib0450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.01.008_bib0455","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0460","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0465","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0470","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall\u2019Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.neurol.2024.01.008_bib0475","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.01.008_bib0480","doi-asserted-by":"crossref","first-page":"e1179","DOI":"10.1212\/NXI.0000000000001179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","volume":"9","author":"Kim","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.01.008_bib0485","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurol.2024.01.008_bib0490","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0495","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0500","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.4049\/jimmunol.1501761","article-title":"Early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition","volume":"198","author":"Arumugakani","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0505","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for\u00a0\u2265\u00a04 years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.01.008_bib0510","doi-asserted-by":"crossref","first-page":"595547","DOI":"10.3389\/fneur.2020.595547","article-title":"Anti-CD20 B cell treatment for relapsing multiple sclerosis","volume":"11","author":"Roach","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0515","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.01.008_bib0520","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0525","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurol.2024.01.008_bib0530","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1474-4422(20)30081-8","article-title":"Interleukin-6 receptor blockade for the treatment of NMOSD","volume":"19","author":"Levy","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0535","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0540","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.01.008_bib0545","doi-asserted-by":"crossref","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.01.008_bib0550","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0555","unstructured":"European Medicines Agency. European public assessment reports ravulizumab 2023. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ultomiris-h-c-004954-ii-0032-epar-assessment-report-variation_en.pdf (accessed November 27, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0560","unstructured":"European Medicines Agency. European public assessment reports satralizumab 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/enspryng-epar-public-assessment-report_en.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0565","unstructured":"European Medicines Agency. European public assessment reports inebilizumab 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/uplizna-epar-public-assessment-report_en.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0570","unstructured":"European Medicines Agency. European public assessment reports eculizumab 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/soliris-h-c-791-ii-0105-epar-assessment-report-variation_en.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0575","unstructured":"Commission de la transparence. Avis de la Commission de la transparence inebilizumab 2022. https:\/\/has-sante.fr\/upload\/docs\/evamed\/CT-19869_UPLIZNA_PIC_INS_AvisDef_CT19869_EPI756.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0580","unstructured":"Commission de la transparence. Avis de la Commission de la transparence satralizumab 2022. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-19456_ENSPRYNG_PIC_INS_AvisDef_CT19456_EPI745.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0585","unstructured":"Commission de la transparence. Avis de la Commission de la transparence eculizumab 2020. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-18643_SOLIRIS_NMOSD_PIC_EI_AvisDef_CT18643_EPI678.pdf (accessed July 2, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0590","unstructured":"Commission de la transparence. Avis de la Commission de la transparence ravulizumab 2023. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-20332_ULTOMIRIS_PIC_EI_AvisDef_CT20332_EPI789.pdf (accessed November 27, 2023)."},{"key":"10.1016\/j.neurol.2024.01.008_bib0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurol.2024.01.008_bib0600","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","article-title":"Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis","volume":"270","author":"Yin","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0605","doi-asserted-by":"crossref","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.01.008_bib0610","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in patients with AQP4-Ab, MOG-Ab or double-negative neuromyelitis optica disorder","author":"Collongues","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0615","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/13524585221130934","article-title":"Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society","volume":"29","author":"Vukusic","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2024.01.008_bib0620","doi-asserted-by":"crossref","first-page":"103356","DOI":"10.1016\/j.msard.2021.103356","article-title":"AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"57","author":"Marignier","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.01.008_bib0625","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.01.008_bib0630","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207443","article-title":"Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder","author":"Demuth","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.01.008_bib0635","doi-asserted-by":"crossref","first-page":"101883","DOI":"10.1016\/j.msard.2019.101883","article-title":"Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: a case report","volume":"39","author":"Ashtari","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.01.008_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T19:33:33Z","timestamp":1737574413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724004764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":64,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0035378724004764"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.01.008","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}